Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Ajax Therapeutics has raised $95.0M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
Ajax Therapeutics's investors include RA Capital Management, Vivo Capital, EcoR1 Capital, Goldman Sachs Asset Management, Schrodinger.
Ajax Therapeutics is headquartered in Cambridge, United States.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Ajax Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ajax Therapeutics — Funding & Investors." VCBacked, May 13, 2024, https://www.vcbacked.co/company/ajax-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Ajax Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ajax-therapeutics
{{cite web |title=Ajax Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ajax-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated